ArticleAmerican journal of physiology. Cell physiology2026
Spatial expression of myocardin protein in normal and disease states.
Article in American journal of physiology. Cell physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Vascular smooth muscle cell (VSMC) dedifferentiation, a phenomenon found in virtually all vascular diseases, is characterized by a transcriptional switch from a contractile to a phenotypically modulated state. Myocardin (MYOCD) is a smooth muscle cell-restricted coactivator that is necessary and sufficient for the differentiation of VSMC through the transcriptional activation of SMC-restricted cytoskeletal and contractile genes. Despite 25 yr of research on MYOCD, the reliable expression of this protein continues to be poorly represented and understood. Accordingly, we generated a novel rat model carrying HA-tagged MYOCD to address pervasive disparities in the literature and elucidate MYOCD protein expression in vivo. Western blotting studies documented the highest MYOCD protein expression in aorta, bladder, and uterus, with low or undetectable expression in all other tissues of the rat, including heart. Predictive modeling supports the C-terminus of MYOCD to be most immunoreactive, where the HA tag and one other commercial immunogen reside. Of note, the latter immunogen was used to generate what appears to be the most trustworthy commercial antibody against MYOCD. In vitro transcription/translation and phosphatase treatment of ectopic and endogenous MYOCD protein reveal an intrinsically high molecular weight of MYOCD that has eluded prior reports. Importantly, we present the very first spatial expression profile of MYOCD protein in several mouse and rat tissues under baseline and vascular injury conditions. The results offer the SMC community new resources and insight into the reliable detection of MYOCD protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.